Updated on 16 March 2016
Baxter International has announced the enrollment of the first patient in a US clinical trial
Singapore: Baxter International has announced the enrollment of the first patient in a US clinical trial for VIVIA, an investigational home hemodialysis (HD) system being developed by Baxter and DEKA Research & Development Corporation.
The trial is designed to study more frequent, extended duration nocturnal home HD therapy (High Dose HD), which will be performed in dialysis facilities as well as the home setting. The study is assessing safety of the product and adequacy of dialysis.
The VIVIA investigational home hemodialysis system includes an integrated water purification module, safety sensors and one-button fluid infusion. The investigational system also features SHARESOURCE, Baxter's two-way connectivity platform that allows physicians and nurses to monitor patients' historical treatment results remotely.